FDA Fast Track Designation Sends Biotech Soaring Mid-Week

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, February 12, 2025

A California-based biotech found some serious success on Wednesday after the company received FDA fast track designation for Troculeucel, used for the treatment of moderate Alzheimer’s disease.

Naturally traders rushed to buy up share of NKGen Biotech Inc. (Nasdaq:NKGN), pushing shares of the micro cap to close up at $0.8418/share (+121.64%) on the day. This mid-week success could be an indication that the stock has officially broken out from a multi-month downtrend, and might be headed to greener pastures.

NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited about the work we are doing to strengthen the immune system.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.